| Literature DB >> 26171177 |
Guangquan Wei1, Xiaowei Kang1, Xianping Liu1, Xing Tang1, Qinlong Li2, Juntao Han3, Hong Yin1.
Abstract
Regardless of the controversial pathogenesis, intracranial meningeal hemangiopericytoma (M-HPC) is a rare, highly cellular and vascularized mesenchymal tumor that is characterized by a high tendency for recurrence and extraneural metastasis, despite radical excision and postoperative radiotherapy. M-HPC shares similar clinical manifestations and radiological findings with meningioma, which causes difficulty in differentiation of this entity from those prognostically favorable mimics prior to surgery. Treatment of M-HPC, particularly in metastatic settings, remains a challenge. A case is described of primary M-HPC with recurrence at the initial and distant intracranial sites and extraneural multiple-organ metastases in a 36-year-old female. The metastasis of M-HPC was extremely extensive, and to the best of our knowledge this is the first case of M-HPC with delayed metastasis to the bilateral kidneys. The data suggests that preoperative computed tomography and magnetic resonance imaging could provide certain diagnostic clues and useful information for more optimal treatment planning. The results may imply that novel drugs, such as temozolomide and bevacizumab, as a component of multimodality therapy of M-HPC may deserve further investigation.Entities:
Keywords: brain tumor; computed tomography treatment; magnetic resonance imaging; meningeal hemangiopericytoma; metastasis
Year: 2015 PMID: 26171177 PMCID: PMC4487068 DOI: 10.3892/mco.2015.537
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450